We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Novartis AG (NVS) ADR Each Repr 1 CHF0.50 (Reg D)

Sell:$93.08 Buy:$93.09 Change: $1.34 (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:$93.08
Buy:$93.09
Change: $1.34 (1.42%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:$93.08
Buy:$93.09
Change: $1.34 (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Contact details

Address:
Lichtstrasse 35
BASEL
4056
Switzerland
Telephone:
+41 (61) 3241111
Website:
https://www.novartis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NVS
ISIN:
US66987V1098
Market cap:
$207.25 billion
Shares in issue:
2.04 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Vasant Narasimhan
    Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch
    Chief Financial Officer, Member of the Executive Committee
  • Robert Kowalski
    Chief People and Organization Officer, Member of the Executive Committee
  • Klaus Moosmayer
    Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
  • Shreeram Aradhye
    President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
  • Victor Bulto
    President - Innovative Medicines US, Member of the Executive Committee
  • Aaron Gal
    Chief Strategy and Growth Officer, Member of the Executive Committee
  • Karen Hale
    Chief Legal Officer, Member of the Executive Board
  • Patrick Horber
    President - International, Member of the Executive Board
  • Steffen Lang
    President - Operations, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.